Organic compounds -- part of the class 532-570 series – Organic compounds – Carboxylic acids and salts thereof
Reexamination Certificate
2000-05-03
2001-04-03
Killos, Paul J. (Department: 1623)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carboxylic acids and salts thereof
C562S584000
Reexamination Certificate
active
06211407
ABSTRACT:
TECHNICAL FIELD
This invention relates to novel compounds, dicreatine and tricreatine citrate, and a method of making those products.
BACKGROUND OF THE INVENTION
Creatine monohydrate (hereinafter “creatine”) is a naturally occurring metabolite found in red muscle tissue. It plays an important role in energizing the muscle. Creatine phosphate is used by the body to recycle ADP to ATP (adenosine triphosphate). ATP is stored in the mitochondria of muscle cells and produces energy when converted into ADP. Muscle fatigue begins when the supply of ATP is lowered.
Synthetic or man-made creatine monohydrate is widely available. Persons interested in and engaging in regular weight lifting regimens for the purpose of body building find that shortly after beginning the use of creatine as a nutritional supplement, muscles take on additional mass and definition.
Synthetic creatine monohydrate is sold in powder form. The powder may be blended with juices or other fluids, and then promptly ingested. Prompt ingestion is important, because creatine is not stable in acidic solutions, such as juices. If creatine is retained in acidic solutions for even relatively short periods of time, most or all of the creatine in this solution turns into creatinine. Creatinine does not have the beneficial effects of creatine.
Creatine monohydrate can be used to manufacture various salts. These salts include, for example, citric and maleic salts.
U.S. Pat. No. 5,973,199 (hereinafter “the '199 patent”) discloses a form of a creatine salt that appears to be a combination of one mole of creatine monohydrate with one mole of citric acid, i.e., a monocreatine citrate. Particularly, Example 1 of the '199 patent discloses the combination of 0.180 moles of monohydrate citric acid with 0.134 moles of creatine monohydrate. A two-to-one or three-to-one molar ratio of creatine to the citric acid would be necessary for the production of a dicreatine or tricreatine salt. Such salts do not appear to be disclosed in the '199 patent.
U.S. Pat. No. 5,925,378 (hereinafter the '378 patent) discloses another form of a creatine citrate. In the '378 patent, as in the '199 patent, there is no disclosure of a creatine citrate that includes a two to one or three to one or more molar ratio of creatine monohydrate to the citric acid, i.e., there is no disclosure of a dicreatine or tricreatine citrate.
It would be desirable to provide another form of creatine that is stable, and that can prevent or impede the conversion of creatine to creatinine. It would further be desirable to provide a form of creatine salt that is other than a monocreatine citrate form of the salt.
SUMMARY OF THE INVENTION
The invention is a dicreatine citrate comprising two creatine cations per citrate dianion. The dicreatine citrate has a melting point of approximately 146° F. The invention is also a tricreatine citrate comprising three creatine cations per citrate trianion. The tricreatine citrate has a melting point of approximately 154° F.
DETAILED DESCRIPTION
While this invention is susceptible of embodiment in many different forms, there is shown in the drawings and will herein be described in detail preferred embodiments of the invention with the understanding that the present disclosure is to be considered as an exemplification of the principles of the invention and is not intended to limit the broad aspect of the invention to the embodiments illustrated.
REFERENCES:
patent: 5863939 (1999-01-01), Pischel et al.
patent: 5886040 (1999-03-01), Fang
patent: 5925378 (1999-07-01), Carnazzo
patent: 5973199 (1999-10-01), Negrisoli et al.
patent: 5994581 (1999-11-01), Fang
Chaudhry Mahreen
Killos Paul J.
Pfanstiehl Laboratories, Inc.
Wallenstein & Wagner Ltd.
LandOfFree
Dicreatine citrate and tricreatine citrate and method of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dicreatine citrate and tricreatine citrate and method of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dicreatine citrate and tricreatine citrate and method of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2500127